Skip to main content

Table 3 Cancer staging and recommended management based on the original and se1cond opinion radiology reports compared to the pathologic staging gold standard (n = 30)

From: Impact of neuroradiologist second opinion on staging and management of head and neck cancer

     

Staging

  

Management

 

Pt

Age

M/F

Primary

Original

Second opinion

Pathologic

Original

Second opinion

Actual

A

89

F

Oral Cavity

TxN0

T4aN2b

T4aN0

Don’t know†

Surgery

Surgery

B

55

M

Oral Cavity

T0N0

T1N1

T2N1

No treatment

Surgery

Surgery

C

84

F

Oral Cavity

T2N0

T2N0

T2N2b

Surgery

Surgery

Surgery

D

40

M

NC & PNS

T0N0

T3Nx

T3Nx

No treatment

Don’t know‡

Surgery

E

51

F

Oral Cavity

TxN0

TxN0

TisN0

Surgery*

Surgery*

Surgery

F

36

M

Oral Cavity

TxNx

T4aN0

T4aN0

Don’t know†

Don’t know‡

Surgery

G

68

M

Larynx

TxNx

T1N0

T1N0

Don’t know†

Surgery

Surgery

H

75

F

Oral Cavity

T1N2b

T1N2b

T1N2c

Surgery

Surgery

Surgery

I

74

M

Salivary Gland

T2N0

T2N0

T2N0

Surgery

Surgery

Surgery

J

69

M

Larynx

T4aN1

T4aN2b

T4aN1

Surgery

Surgery

Surgery

K

61

M

Oral Cavity

TxN0

T2N0

T2N0

Don’t know†

Surgery

Surgery

L

80

F

Oral Cavity

T2N0

T1N1

T2N2b

Surgery

Surgery

Surgery

M

54

M

Oropharynx

TxN1

T1N1

T1N1

RT§

RT§

Surgery

N

82

F

Oral Cavity

T0N0

T0N0

T0N0

Don’t know‡

Don’t know‡

Surgery

O

49

F

Oral Cavity

T0N0

T1N0

T1N0

No treatment

Don’t know‡

Surgery

P

70

M

Larynx

T4aN0

T4aN2c

T4aN0

Surgery

Surgery

Surgery

Q

90

M

Oral Cavity

TxN1

T2N1

T2N1

Don’t know†

Don’t know‡

Surgery

R

85

F

NC & PNS

TxN0

T4aN0

T4aN0

Don’t know†

Don’t know◊

Surgery

S

56

M

Oral Cavity

TxN0

T4aN0

T4aN2b

Surgery*

Surgery

Surgery

T

58

M

Oral Cavity

T4aNx

T4aN2c

T4aN1

Don’t know†

Surgery

Surgery

U

45

M

Salivary Gland

T1N0

T1N0

T1N0

Surgery

Surgery

Surgery

V

88

F

Oral Cavity

TxN1

T4aN1

T4aN1

Don’t know†

Surgery

Surgery

W

56

F

Oral Cavity

T0N0

TxN0

TisN0

No treatment

Don’t know‡

Surgery

X

43

M

Oropharynx

TxN2a

T2N2b

T2N2b

Don’t know†

RT§

Surgery

Y

50

F

Oral Cavity

T1N0

T1N0

T1N0

Don’t know‡

Don’t know‡

Surgery

Z

81

M

Oral Cavity

TxN1

T2N2b

T2N2b

Don’t know†

Surgery

Surgery

AA

81

M

Skin

TxN2b

TxN2b

TxN2b

Don’t know◊

Don’t know◊

Surgery

AB

58

F

Oral Cavity

T2N2b

T2N2b

T2N2b

Don’t know‡

Don’t know‡

Surgery

AC

63

F

Salivary Gland

T3N0

T4aN2b

T4aN1

Surgery

Surgery

Surgery

AD

65

M

Oral Cavity

TxN1

T2N2b

T2N2b

Don’t know†

Surgery

Surgery

  1. F, Female; M, Male; NC & PNS, Nasal Cavity and Paranasal Sinuses; Pt, Patient Identifier; RT, Radiotherapy (+/−chemotherapy).
  2. * Biopsy proven oral cavity cancer was stated in the Clinical History section of the report.
  3. † Insufficient information in the report to make a recommendation.
  4. ‡ Technically inadequate or incomplete scan; the radiologist recommended additional imaging.
  5. § Oropharyngeal carcinoma is usually treated with primary radiotherapy (+/−chemotherapy) at our institution.
  6. â—Š Post-treatment recurrence; the surgeon needed details of prior treatment before making a salvage treatment decision.